BG
LRMR icon

BlackRock Group’s Larimar Therapeutics LRMR Stock Holding History

BlackRock Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-468
Closed -$37K – 3034
2016
Q1 		$37K Buy
468
+212
+83% +$16.7K ﹤0.01% 2976
2015
Q4 		$19K Sell
256
-9
-3% -$1.45K ﹤0.01% 2948
2015
Q3 		$101K Buy
265
+58
+28% +$26.1K ﹤0.01% 2704
2015
Q2 		$86K Buy
+207
New +$86.6K ﹤0.01% 2789

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

BlackRock Group's LRMR Position: Q2 2016 in Review

BlackRock Group sold out of Larimar Therapeutics (LRMR) in Q2 2016, closing a stake of 468 shares — an estimated $37K sold.

BlackRock Group first reported a position in LRMR in Q2 2015 and held it in 4 quarters. The position peaked at $101K in Q3 2015. 73 funds tracked by Wall St. Rank hold LRMR as of Q2 2016.

  • BlackRock Group reported no remaining Larimar Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Group sold 468 Larimar Therapeutics shares in Q2 2016, an estimated $37K.
  • BlackRock Group first reported a position in Larimar Therapeutics in Q2 2015 and held it in 4 quarters.
  • BlackRock Group's Larimar Therapeutics position peaked at $101K in Q3 2015.
  • 73 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.